Season 3 - Ep.23: Extended interview on Optimising drug therapy in chronic coronary syndromes

8 snips

Sep 25, 2025

In this engaging discussion, Professor Robert Storey, a renowned cardiologist and director at the University of Sheffield, shares his expertise on chronic coronary syndromes. He dives into the effectiveness of anti-anginal medications and how lifestyle changes can dramatically relieve symptoms. The conversation also covers the benefits of PCI in reducing medication needs and the complexities of beta blocker side effects. Robert emphasizes the importance of careful management in antithrombotic therapy, highlighting when it's appropriate to consider stopping these treatments.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Medical Therapy Can Strongly Relieve Angina

Anti-anginal drugs plus lifestyle changes can profoundly improve or even completely relieve angina symptoms.
Revascularisation helps mainly when physiologically relevant epicardial stenosis exists because microvascular disease often coexists.

ADVICE

Individualise Choice Between Drugs And PCI

Discuss patient preferences and tolerance when choosing between conservative therapy and PCI.
Consider PCI if adverse effects or blood pressure limits prevent escalation of anti-anginal drugs.

INSIGHT

Beta-Blocker Side Effects Are Unpredictable

Beta-blocker adverse effects are common but often mild and unpredictable in who will be significantly affected.
Some adverse effects can substantially reduce quality of life, so selection matters.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Host: Susanna Price

Guest: Robert Storey

Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview

Disclaimer:

ESC TV Today is supported by Bristol Myers Squibb and Novartis.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

The ESC is not liable for any translated content of this video. The English-language always prevails.

Declarations of interests:

Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.